AMLX241220P4000
- 0.15
- 0.000.00%
Amylyx Pharmaceuticals Newsroom
Baird Upgrades Amylyx Pharmaceuticals(AMLX.US) to Buy Rating, Raises Target Price to $11
Amylyx Pharmaceuticals Raised to Outperform From Neutral by Baird
Strong Buy Rating for Amylyx Pharmaceuticals Inc. Driven by Promising Avexitide Prospects and Stable Financial Standing
Cautious Hold on Amylyx Pharmaceuticals Amid Uncertainty in Pipeline Progress
Amylyx Pharma Analyst Ratings
H.C. Wainwright Maintains Amylyx Pharmaceuticals(AMLX.US) With Buy Rating, Raises Target Price to $12
BofA Securities Maintains Amylyx Pharmaceuticals(AMLX.US) With Buy Rating
Amylyx Upgraded to Buy by BofA on Hypoglycemia Drug Potential
BofA Securities Upgrades Amylyx Pharmaceuticals(AMLX.US) to Buy Rating, Announces Target Price $10
Analysts Offer Insights on Healthcare Companies: Intra-Cellular Therapies (ITCI), Amylyx Pharmaceuticals Inc (AMLX) and Intuitive Surgical (ISRG)
Neutral Stance on Amylyx Pharmaceuticals Amid Promising Data and Uncertainties
Leerink Partners Maintains Amylyx Pharmaceuticals(AMLX.US) With Hold Rating, Announces Target Price $4
H.C. Wainwright Maintains Amylyx Pharmaceuticals(AMLX.US) With Buy Rating, Maintains Target Price $8
HC Wainwright & Co. Reiterates Buy on Amylyx Pharma, Maintains $8 Price Target
Amylyx Pharma Analyst Ratings
Analysts' Top Healthcare Picks: Neumora Therapeutics, Inc. (NMRA), Amylyx Pharmaceuticals Inc (AMLX)
Mizuho Securities Maintains Amylyx Pharmaceuticals(AMLX.US) With Hold Rating, Announces Target Price $3
Analysts Conflicted on These Healthcare Names: Amylyx Pharmaceuticals Inc (AMLX), Taysha Gene Therapies (TSHA) and Lexeo Therapeutics, Inc. (LXEO)
Bank of America Securities Keeps Their Hold Rating on Amylyx Pharmaceuticals Inc (AMLX)
Buy Rating Affirmed for Amylyx Pharmaceuticals Amid Promising Drug Trials and FDA Breakthrough Designation